Within commercial oral solid dosage manufacturing for ruminant antiparasitics, the selection of direct compression versus wet granulation for bithionol sulfoxide pharmaceutical grade API is governed by the crystalline morphology of the material as discharged from micronization units and the triboelectric charging behavior that emerges during transfer through intermediate bulk containers. The sulfoxide derivative retains two ionizable phenolic groups, and unless the crystalline habit is controlled through solvent-mediated recrystallization using ethanol:water mixtures under controlled cooling, anisotropic needle growth can yield bulk powders with Carr compressibility indices exceeding 25, a threshold that precludes reliable die fill on high-speed rotary tablet presses operating at turret speeds above 30 rpm. Consequently, wet granulation in a high-shear mixer fitted with torque rheometry is the default manufacturing route for bithionol sulfoxide oral bolus tablets intended for bovine fascioliasis control. The API is first charged through a 500 μm stainless steel sieve and pre-blended with microcrystalline cellulose and pregelatinized starch in a ratio that permits uniform distribution of the active before binder addition. API loadings in the tablet core typically occupy 20-40% w/w when formulated as a 500 mg bolus with a total core mass of 1.25-2.50 g. A representative core formulation comprises 30-35% w/w active pharmaceutical ingredient, 25-30% w/w microcrystalline cellulose (PH102 grade), 15-20% w/w pregelatinized starch, 5-8% w/w povidone K30 as binder, 3-5% w/w croscarmellose sodium as disintegrant, and 0.5-1.0% w/w magnesium stearate as lubricant. The active substance specification must conform to applicable pharmacopoeial monograph requirements where one exists; where no monograph is published for bithionol sulfoxide, the API specification is established and justified by the finished product manufacturer in accordance with ICH Q3A (impurities), ICH Q3C (residual solvents), and ICH Q3D (elemental impurities), with assay determined by HPLC-UV and identity confirmed by infrared spectroscopy.The high-shear wet granulation process for bithionol sulfoxide bolus production begins with the dry blending step in a vertical granulator equipped with a main impeller and side chopper. The binder solution, prepared as an aqueous dispersion of povidone K30 at 2-5% w/w relative to dry granulate mass, is added through a peristaltic metering pump at a controlled rate while the impeller operates at 150-250 rpm and the chopper at 1500-3000 rpm. The granulation endpoint is determined by torque rheometry, with the target torque value correlating to a wet mass with sufficient plasticity for subsequent extrusion without being overly wetted. Batch-to-batch variance in endpoint torque is a recognized processing bottleneck; torque sensors on inline granulators resolve this by enabling a defined power consumption cutoff rather than relying on fixed mixing time. Following wet massing, the granulate is discharged into a fluid bed dryer and dried at inlet air temperature of 45-55°C to a final loss-on-drying specification of 0.5-2.0% w/w. Exceeding 55°C may induce partial amorphous conversion at the granule surface, and because published polymorphic stability data specific to bithionol sulfoxide is limited, conservative drying is specified to minimize risk of form conversion during scale-up. The dried granulate is milled through a 800 μm screen using a conical mill operating at 1500-2000 rpm, then blended with croscarmellose sodium and magnesium stearate in a bin blender for 15-20 min at 12-15 rpm. Over-lubrication beyond 20 min is avoided due to hydrophobic film formation on granule surfaces that can retard disintegration in ruminal fluid. Compression is performed on an instrumented rotary tablet press fitted with 19 mm oval tooling at a target compression force of 10-20 kN, producing tablets with hardness of 8-12 kP measured by a calibrated hardness tester conforming to USP <1217> Tablet Breaking Force. In-process controls include weight variation testing at 15-min intervals, hardness testing, thickness measurement, and periodic friability testing per USP <1216> with an acceptance limit of ≤ 1.0% weight loss. Film coating, where specified, is performed in a side-vented pan coater using an aqueous hydroxypropyl methylcellulose-based coating system applied to a weight gain of 2-3%; coating inlet air temperature is maintained below 60°C to avoid thermal stress on the API.

Representative process parameter ranges for bithionol sulfoxide veterinary bolus granulation

Parameter	Method / Equipment	Representative Control Range	Purpose
Granule moisture content	Loss-on-drying at 105°C	0.5-2.0% w/w	Ensures compressibility without capping or sticking
Granule bulk density	USP <616> Method I	0.45-0.65 g/mL	Controls die fill consistency on rotary press
Binder concentration	PVP K30 aqueous solution	2-5% w/w of dry granulate	Controls granule strength and wet mass viscosity
Compression force	Instrumented rotary tablet press	10-20 kN	Achieves hardness without over-lubrication defects
Tablet hardness	USP <1217> breaking force	8-12 kP	Ensures intactness during veterinary handling and packaging
Disintegration time	USP <701>	≤ 15 min	Confirms release in simulated rumen fluid
Content uniformity	USP <905>	Acceptance value ≤ 15	Confirms batch homogeneity at individual tablet level

The finished bithionol sulfoxide oral bolus tablet is designated for oral administration to cattle and sheep for the control of mature and immature Fasciola hepatica infections. Finished product release testing requires confirmation of identity, assay, content uniformity per USP <905>, disintegration per USP <701>, dissolution where specified using Apparatus I (basket) at 100 rpm in 900 mL simulated ruminal fluid at pH 6.8 and 37°C, microbial limits per USP <61> and USP <62>, and related substances by HPLC-UV. Compliance with 21 CFR Part 211.84 requires identity verification of each incoming API container; 21 CFR Part 211.113 requires written procedures for microbiological control during granulation, drying, and compression. Regulatory acceptance of the product requires conformance to EU Regulation 2019/6 on veterinary medicinal products, and where the product is registered in multiple jurisdictions, stability data generated under VICH GL3 (stability testing of new veterinary drug substances and products) must support the assigned shelf life in the selected packaging configuration.

What Drives Moisture Uptake in Gelatin Capsule Filling of Bithionol Sulfoxide APIs?

Moisture ingress during automatic capsule filling of bithionol sulfoxide pharmaceutical grade API is governed by the hygroscopic tendency of the micronized drug substance, the equilibrium relative humidity of the powder blend, and the water content of the gelatin shell itself. Because bithionol sulfoxide exhibits a chlorinated bisphenol structure with ionizable phenolic groups, the substance can retain surface moisture when micronized to reduce particle size for content uniformity purposes. Micronization is performed using a spiral jet mill with compressed nitrogen or dried compressed air at a feed rate calibrated to achieve a target particle size distribution of D₉₀ ≤ 20 μm as verified by laser diffraction per ISO 13320:2020. The micronized API is then conditioned in a controlled environment at 35-40% relative humidity and 20-25°C for a minimum of 24 h before blending to stabilize surface moisture below 1.0% w/w as determined by Karl Fischer titration. Capsule fill formulations for bithionol sulfoxide typically contain 30-50% w/w API per filled mass, with the balance comprising lactose monohydrate, microcrystalline cellulose, and colloidal silicon dioxide. For a 100 mg strength capsule, the total fill mass is normally 300-400 mg; for a 250 mg strength capsule, the fill mass is 500-650 mg, requiring capsule sizes 0 through 00 depending on bulk density. Dry blending is performed in a low-shear tumble blender at 15-20 rpm for 20-30 min, with magnesium stearate added as a lubricant at 0.5-1.0% w/w during the final 3-5 min of blending. Filling is carried out on a fully automatic capsule machine equipped with tamping pins or a dosator unit; tamping pin machines require a pre-compression step that densifies the powder bed to a target plug density of 0.60-0.75 g/mL to ensure sufficient fill weight without over-compaction. In-process weight verification is performed using a checkweigher with ±5% individual capsule weight acceptance criteria, and machine output is limited to 60-80% of maximum rated speed on the first production batches to evaluate powder flow stability under prolonged running.Batch-to-batch variance in API moisture content is a recognized processing bottleneck for capsule filling of chlorinated bisphenol derivatives; when the equilibrium moisture content of the powder blend rises above 2.0% w/w, powder flow deterioration produces weight variation and segregation of the active ingredient from the filler matrix. Equipment-level mitigation includes equipping the capsule machine with a dehumidified process enclosure maintained at 30-35% relative humidity and 20-23°C dry bulb temperature. The finished hard gelatin capsules are packaged in aluminum-aluminum blister packs with desiccant sachets containing molecular sieve or silica gel, and the packaging specification includes a moisture permeation test with an acceptance limit of ≤ 0.5 mg/day/package at 40°C and 75% relative humidity. Release testing includes assay, content uniformity per USP <905>, dissolution per USP <711> using Apparatus II (paddle) at 75 rpm in 900 mL of pH 6.8 phosphate buffer with 0.5% sodium lauryl sulfate at 37°C, identification by HPLC retention time matching, and microbiological examination per USP <61> and USP <62>. Compliance with 21 CFR Part 211.113 requires documented environmental monitoring of the capsule filling suite and validation of the dehumidification system; compliance with VICH GL18 requires that residual solvent levels in the micronized API do not exceed the permitted daily exposure limits for Class 2 solvents, verified at batch release using headspace gas chromatography. The terminal finished product type is a hard gelatin oral capsule containing 100 mg or 250 mg bithionol sulfoxide, for administration to lambs, calves, and adult sheep where the target dose and species-specific label claim are determined by the marketing authorization holder.

Medicated Premix Granulation and Homogeneity Thresholds

The incorporation of bithionol sulfoxide pharmaceutical grade API into medicated feed premixes for sheep and cattle operates under a fundamentally different quality paradigm than tablet or capsule manufacturing because the active pharmaceutical ingredient is diluted to trace levels before reaching the animal. The premix formulation typically contains 1-5% w/w bithionol sulfoxide dispersed in a carrier matrix of ground limestone, wheat middlings, or corn cob fractions, with the API first pre-blended with colloidal silicon dioxide at 0.5-1.0% w/w to reduce electrostatic adhesion to stainless steel blender walls. Stepwise geometric dilution is performed in a ribbon blender or paddle mixer until the API concentration reaches the target premix strength, after which the blend is granulated using a fluid bed spray granulator with an aqueous binder solution of hydroxypropyl methylcellulose or starch paste. Granulation serves two functions: it stabilizes the API distribution within the carrier matrix to prevent segregation during transport and storage, and it reduces dust generation during premix handling by producing granules with a particle size distribution of 500-1000 μm determined by sieve analysis per USP <811>. The final feed mill incorporation rate is calculated from the target oral dose expressed in mg/kg body weight and the estimated daily dry matter intake of the target species; typical incorporation rates in complete feed are in the range of 50-500 mg of bithionol sulfoxide per kg of feed (equivalent to 0.005-0.05% w/w), although the exact rate is species-dependent and must be established through veterinary oversight and regional feed regulations. Homogeneity of the medicated feed batch is verified by collecting 10 samples at predetermined sampling points across the mixer discharge using a thief probe, with the active content of each sample quantified by HPLC-UV. Acceptance criteria follow EU Regulation 2019/4 Annex III requirements, which specify that the coefficient of variation of the active substance concentration across samples should not exceed 10% for homogenized feed. Compliance with 21 CFR Part 558 applies where the medicated feed is distributed in the United States, and compliance with GMP+ BA10 applies to premix production in European markets, with the additional requirement that dedicated or validated cleaning procedures per 21 CFR 211.67 are implemented to prevent carry-over of bithionol sulfoxide into subsequent non-medicated feed batches. The terminal finished product type is a medicated feed premix granule for dilution by licensed feed mills into complete ruminant feed, with a labeled withdrawal period established by the marketing authorization holder and verified by tissue residue studies conducted under VICH GL48 or applicable regional residue regulations.Because the sulfoxide derivative of bithionol retains the lipophilic chlorinated bisphenol core while the polar sulfoxide moiety introduces only marginal aqueous miscibility, sterile injectable formulation development confronts a solubility-pH conflict that cannot be resolved without a co-solvent and alkalizing buffer system. The phenolic groups of bithionol sulfoxide undergo deprotonation at alkaline pH, and ionization increases aqueous solubility by converting the uncharged molecule to a phenolate species; however, published solubility data specifically for bithionol sulfoxide injectable formulations is limited, and the solubility-pH profile must be experimentally established for each specific co-solvent composition. Formulation development typically evaluates a vehicle comprising 10-30% v/v propylene glycol or polyethylene glycol 400, 5-15% v/v benzyl alcohol as preservative and co-solvent, and water for injection adjusted with sodium hydroxide or tromethamine to a target pH of 8.0-9.5. The active pharmaceutical ingredient is targeted at 50-150 mg/mL in the final injectable solution, with the upper concentration limit constrained by precipitation risk upon dilution with physiological fluids at the injection site. Precipitation at the injection site is a recognized operational boundary for injectable anthelmintic suspensions; if the formulation precipitates upon exposure to muscle interstitial fluid at pH 7.4, local tissue irritation and reduced systemic bioavailability may occur. Consequently, a dilution stability study is performed by spiking 1.0 mL of the formulation into 50 mL of pH 7.4 phosphate-buffered saline at 37°C and monitoring the solution for visible precipitation and light obscuration particle count over 24 h; formulations that fail this test require adjustment of co-solvent ratio or reduction of API concentration. The bulk solution is prepared under nitrogen blanketing to minimize oxidative degradation, with sodium metabisulfite added at 0.1% w/v as an antioxidant where compatibility is demonstrated. Because bithionol sulfoxide contains four chlorine atoms per molecule, terminal sterilization by autoclave at 121°C for 15 min is conditionally applicable; however, thermal degradation of sulfoxide-containing compounds at elevated pH can generate sulfone and chloride cleavage byproducts, and published stability data for this specific configuration is limited. Aseptic filtration through a sterilizing-grade 0.22 μm PVDF or polyethersulfone membrane filter is therefore the default sterilization route, with filter integrity testing by bubble point or diffusion performed before and after filtration according to filter manufacturer specifications. The filtered bulk solution is aseptically filled into depyrogenated borosilicate glass vials of 50 mL, 100 mL, or 250 mL nominal capacity, stoppered with bromobutyl rubber closures, and sealed with aluminum flip-off seals. Filling is performed in an ISO 14644-1:2015 Class 5 environment (equivalent to EU GMP Annex 1 Grade A) with surrounding Grade B controlled area, and environmental monitoring of viable and non-viable particulates is maintained throughout the filling campaign.

Sterile injectable quality attribute compliance matrix for bithionol sulfoxide solution

Quality Attribute	Test Method / Standard	Acceptance Criterion / Control Limit	Verification Point
Sterility	USP <71>, EP 2.6.1	No growth after 14 days incubation	Finished product
Bacterial endotoxins	USP <85>, EP 2.6.14	≤ 0.5 EU/mg API	Bulk solution, finished product
Particulate matter	USP <788> Light Obscuration	≥ 10 μm: ≤ 6000/container; ≥ 25 μm: ≤ 600/container	Finished product
pH	USP <791>	8.0-9.5	Bulk solution, finished product
Assay	HPLC-UV, ICH Q2(R1) validated	95.0-105.0% of label claim	Bulk solution, finished product
Related substances	ICH Q3A, VICH GL18	Individual impurity ≤ 0.5%; total ≤ 2.0%	API, bulk solution, finished product
Residual solvents	ICH Q3C Class 2	Within permitted daily exposure	API
Elemental impurities	ICH Q3D	Class 1 elements within permitted daily exposure	API, bulk solution
Sterile filter integrity	Bubble point / diffusion	Per filter manufacturer specification	Pre- and post-filtration
Visible particles	USP <790>	Essentially free from visible particles	100% inspection of finished product

The sterile injectable bithionol sulfoxide solution is designated for intramuscular or subcutaneous administration to cattle, sheep, and goats where a parenteral route provides therapeutic advantage over oral dosing, such as in animals with reduced feed intake or severe fascioliasis. The terminal finished product type is a sterile injectable solution packaged in single-dose or multi-dose glass vials with a specified in-use shelf life after first broach, supported by in-use stability data generated according to VICH GL3 and by antimicrobial effectiveness testing per USP <51> and EP 5.1.3 where a multi-dose presentation is authorized. Sterility assurance is validated through media fill studies performed at least semi-annually with a minimum of 3000 units per validation run per EU GMP Annex 1 Section 9.2, and the target contamination rate is 0 contaminated units per validation run. Batch release requires documented review of all critical process parameters including bulk solution pH, filter integrity results, fill weight control charts, and environmental monitoring data. The operational boundary for storage is defined by stability data generated at 25°C / 60% relative humidity and 40°C / 75% relative humidity per VICH GL3, with the assigned shelf life limited by the earliest confirmed failure in assay, related substances, pH drift, or particulate matter.

When Aqueous Suspension Rheology Limits Drench Accuracy in Sheep

Oral drench formulations of bithionol sulfoxide for sheep and cattle present a distinct manufacturing challenge because the active pharmaceutical ingredient is suspended rather than dissolved, and the rheological properties of the suspension directly control the volumetric accuracy of drench gun delivery. A suspension formulation targeting 25-100 mg/mL bithionol sulfoxide is prepared by first dispersing the micronized API (D₉₀ ≤ 10 μm) in an aqueous vehicle containing a wetting agent such as polysorbate 80 at 0.05-0.2% w/w. Wet milling is performed using a colloid mill or a bead mill charged with 0.6-1.0 mm zirconium oxide beads, with the milling duration adjusted to achieve a particle size that remains below the sedimentation threshold. After milling, the suspending agent—either xanthan gum at 0.1-0.3% w/w or sodium carboxymethylcellulose at 0.2-0.5% w/w—is hydrated in the vehicle and blended with the milled API concentrate. The suspension is then pH-adjusted to 6.0-7.0 using citric acid or sodium hydroxide, and preservatives methylparaben (0.18% w/w) and propylparaben (0.02% w/w) are added to prevent microbial proliferation during the in-use period. Sedimentation volume and redispersibility are the two critical quality attributes for this dosage form; sedimentation volume is determined by recording the settled bed height relative to total suspension height after 24 h, with a target sedimentation volume ratio of ≥ 0.90, and redispersibility is confirmed by subjecting the settled suspension to 20 manual inversions and verifying that no hard cake remains on the container bottom. Viscosity is measured at 25°C using a rotational viscometer with spindle LV-2 at 30 rpm, and a target apparent viscosity of 200-800 mPa·s is specified to balance ease of withdrawal through the drench gun nozzle against sedimentation control. Batch-to-batch variance in xanthan gum viscosity from different raw material lots is a known source of drench delivery inaccuracy; this is controlled by establishing a viscosity specification on the hydrated gum solution and by qualifying secondary gum suppliers through comparative rheological testing.The manufacturing process for bithionol sulfoxide oral drench suspension proceeds from high-shear dispersion through wet milling to final filling in 1 L, 2.5 L, or 5 L high-density polyethylene containers fitted with a pump dispenser calibrated to deliver a specified volume per stroke. In-process controls include viscosity, pH, particle size, and active content assay at the start, middle, and end of the filling run to detect sedimentation in the filling line. Compliance for this dosage form includes 21 CFR Part 211 for non-sterile drug manufacturing, USP <51> Antimicrobial Effectiveness Testing for preserved oral liquids, and EP 5.1.3 Efficacy of Antimicrobial Preservation. Stability testing under VICH GL5 (photostability) is required to demonstrate that bithionol sulfoxide does not undergo photolytic degradation during storage in semi-transparent HDPE containers; if photodegradation is observed, amber or opaque packaging is specified. Release testing includes assay by HPLC-UV, preservative content, pH, viscosity, particle size distribution, microbial limits per USP <61> and USP <62>, and sedimentation ratio. The terminal finished product type is an oral drench suspension packaged with a calibrated drench gun or pump dispenser, for direct oral administration to sheep and cattle at a dose volume determined by the label claim and the animal body weight, with the withdrawal period established by target animal residue studies under VICH GL48.Fixed-dose combination bolus formulations containing bithionol sulfoxide and a second anthelmintic agent demand bilayer compression tooling and sequential granulation trains because the compaction profiles of the two active pharmaceutical ingredients rarely overlap across the compression force range available on rotary tablet presses. The rationale for combination therapy is grounded in the complementary spectrum of activity: bithionol sulfoxide targets Fasciola hepatica and other trematodes through interference with mitochondrial oxidative phosphorylation, while a co-formulated anthelmintic such as oxyclozanide or albendazole extends activity against nematode populations or provides synergistic flukicidal effect at differing developmental stages. The manufacturing route for a bilayer bolus begins with the separate wet granulation of each active layer. The bithionol sulfoxide layer is granulated as described for the single-entity bolus tablet, with API loading of 30-50% w/w within that layer. The second active layer is granulated independently using a binder and filler system optimized for the co-formulated anthelmintic; for example, where oxyclozanide is co-formulated at 150 mg per tablet, the second layer may be granulated with lactose monohydrate and povidone K30, with API loading of 20-40% w/w in that layer. The bilayer tablet is compressed on a rotary press equipped with a pre-compression station for the first layer and a main compression station for the final tablet. The first layer is compressed at a force of 4-6 kN to form a coherent but porous layer, and the second layer is then filled over the first layer and compressed at 15-25 kN to form the final bilayer structure. Layer adhesion is the critical quality attribute for this dosage form; insufficient first-layer compression produces excessive first-layer porosity that prevents firm bonding with the second layer, while excessive first-layer compression creates a hard, glazed surface that also resists interfacial bonding. In-process layer separation testing is performed by subjecting the finished tablet to a drop test or by measuring tensile strength at the interface using a diametral compression test, with the acceptance criterion that layer separation does not occur at hardness values within the specified range of 8-14 kP. The operational boundary for bilayer compression is defined by the moisture content differential between the two granulates; if the moisture content of the two layers differs by more than 1.0% w/w at the time of compression, differential elastic recovery after ejection can induce interfacial stress fractures or capping.Regulatory compliance for the fixed-dose combination bolus includes VICH GL23 (studies for bioequivalence) where the combination product is compared to the reference single-entity products, and VICH GL43 (target animal safety) to demonstrate that the co-formulated actives do not produce unexpected adverse events in the target species. Marketing authorization under EU Regulation 2019/6 requires submission of pharmaceutical quality data demonstrating that the two active substances do not undergo chemical interaction during manufacturing or storage; forced degradation studies are performed by subjecting the bilayer tablets to 40°C / 75% relative humidity for 6 months and confirming that no new impurity peaks appear at retention times inconsistent with either active's individual degradation profile. Where the combination bolus is registered for use in food-producing animals, residue depletion studies under VICH GL48 must establish withdrawal periods for both actives simultaneously, accounting for the possibility of metabolic interaction. The terminal finished product type is a bilayer oral bolus tablet containing bithionol sulfoxide and a second anthelmintic agent, for administration to cattle, sheep, and goats, with the specific dose combination, species indications, and withdrawal period established by the marketing authorization holder and confirmed by regional veterinary regulatory authorities.